检索结果-南通市图书馆

Systematic Review and Meta-analysis:immunosuppressive agents for the Treatment of Primary Biliary Cholangitis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Nursing Research 2021年第4期5卷 154-162页

作者： Mengfan Du Bing Xu Ru Xiang Qian Li Yang Chen Yu Fan The Medical Technology College of Shaanxi University of Chinese Medicine Xianyang 712046Shaanxi ProvinceChina The Basic Medical College of Shaanxi University of Chinese Medicine Xianyang 712046Shaanxi ProvinceChina

Background and aim:There are still no clinically satisfactory therapy for *** study was performed to assess the safety and efficacy of IAs for the therapy of ***:Relevant studies were identified and selected by searching PubMed,Web of Science and Cochrane Library *** primary outcome was defined as the need for mortality or liver *** effects and liver biochemical variables were a secondary ***:Nine randomized controlled trials,involving six different treatment regimens with a total of 996 patients,were included in the *** meta-analysis,IAs was not associated with a reduction in risk of mortality or liver transplantation(risk ratio[RR]:0.92,95% confidence interval[CI]:0.69-1.22,P=0.57,P=0%),and have resulted in more adverse effects(RR:1.44,95%CI:1.08-1.92,P=0.01,P=19%).Subgroup analysis showed that IAs monotherapy caused adverse effects such as diarrthea,abdominal pain,and renal insufficiency(RR:1.36,95% CI:1.01-1.82,P=0.04,P=48%).IAs therapy did not prominently improve markers of liver function except for alkaline phosphatases(weighted mean difference[WMD]:-0.38,95% CI:-0.62 to-0.14,P=0.002).Conclusions:IAs cannot reduce the risk of mortality or liver transplantation,whether in IAs monotherapy or combination therapy,and even be associated with more adverse effects.

关键词： Primary biliary cholangitis immunosuppressive agents Meta-analysis

Acute pancreatitis as a complication of acute COVID-19 in kidney transplant recipients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第6期12卷 1104-1110页

作者： Nikolina Basic-Jukic Ivana Juric Lea Katalinic Vesna Furic-Cunko Vibor Sesa Anna Mrzljak Department of Nephrology Arterial HypertensionDialysis and TransplantationUniversity Hospital Centre ZagrebZagreb 10000Croatia Department of Medicine School of MedicineZagreb 10000Croatia Department of Gastroenterology and Hepatology University Hospital Centre ZagrebZagreb 10000Croatia

BACKGROUND Acute pancreatitis is a rare extrapulmonary manifestation of coronavirus disease 2019(COVID-19)but its full correlation with COVID-19 infection remains *** To identify acute pancreatitis’occurrence,clinical presentation and outcomes in a cohort of kidney transplant recipients with acute *** A retrospective observational single-centre cohort study from a transplant centre in Croatia for all adult renal transplant recipients with a functioning kidney allograft between March 2020 and August 2022 to record cases of acute pancreatitis during acute *** were obtained from hospital electronic medical *** acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection was proven by a positive SARS-CoV-2 real-time reverse transcriptase-polymerase chain reaction on the nasopharyngeal *** Four hundred and eight out of 1432(28.49%)patients who received a renal allograft developed COVID-19 *** analyzed cohort included 321 patients(57%males).One hundred and fifty patients(46.7%)received at least one dose of the anti-SARS-CoV-2 vaccine before the *** hundred twenty-five(39.1%)patients required hospitalization,141(44.1%)developed pneumonia and four patients(1.3%)required mechanical *** included immunosuppression modification in 233 patients(77.1%)and remdesivir in 53 patients(16.6%),besides the other supportive *** the study cohort,only one transplant recipient(0.3%)developed acute pancreatitis during acute COVID-19,presenting with abdominal pain and significantly elevated pancreatic *** survived without complications with a stable kidney allograft *** Although rare,acute pancreatitis may complicate the course of acute COVID-19 in kidney transplant *** mechanism of injury to the pancreas and its correlation with the severity of the COVID-19 infection in kidney transplant recipients warrants further research.

关键词： Acute pancreatitis COVID-19 Kidney transplant Angiotensin-converting enzyme-2 receptor immunosuppressive agents

Homoharringtonine promotes heart allograft acceptance by enhancing regulatory T cells induction in a mouse model

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第12期137卷 1453-1464页

作者： Xia Qiu Hedong Zhang Zhouqi Tang Yuxi Fan Wenjia Yuan Chen Feng Chao Chen Pengcheng Cui Yan Cui Zhongquan Qi Tengfang Li Yuexing Zhu Liming Xie Fenghua Peng Tuo Deng Xin Jiang Longkai Peng Helong Dai Medical College Guangxi UniversityNanningGuangxi 530004China Department of Kidney Transplantation Center of Organ TransplantationThe Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China National Clinical Research Center for Metabolic Diseases and Department of Metabolism and EndocrinologyThe Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China Department of Organ Transplantation The Fifth Clinical Medical College of Henan University of Chinese Medicine(Zhengzhou People’s Hospital)ZhengzhouHenan 450000China

Background:Homoharringtonine(HHT)is an effective anti-inflammatory,anti-viral,and anti-tumor protein synthesis inhibitor that has been applied ***,we explored the therapeutic effects of HHT in a mouse heart transplant ***:Healthy C57BL/6 mice were used to observe the toxicity of HHT in the liver,kidney,and hematology.A mouse heart transplantation model was constructed,and the potential mechanism of HHT prolonging allograft survival was evaluated using Kaplan-Meier analysis,immunostaining,and bulk RNA sequencing *** HHT-T cell crosstalk was modeled ex vivo to further verify the molecular mechanism of HHT-induced regulatory T cells(Tregs)***:HHT inhibited the activation and proliferation of T cells and promoted their apoptosis ex *** of 0.5 mg/kg HHT for 10 days significantly prolonged the mean graft survival time of the allografts from 7 days to 48 days(P<0.001)without non-immune *** allografts had long-term survival after continuous HHT treatment for 28 *** significantly reduced lymphocyte infiltration in the graft,and interferon-γ-secreting CD4^(+)and CD8^(+)T cells in the spleen(P<0.01).HHT significantly increased the number of peripheral Tregs(about 20%,P<0.001)and serum interleukin(IL)-10 *** downregulated the expression of T cell receptor(TCR)signaling pathway-related genes(CD4,H2-Eb1,TRAT1,and CD74)and upregulated the expression of IL-10 and transforming growth factor(TGF)-βpathway-related genes and Treg signature genes(CTLA4,Foxp3,CD74,and ICOS).HHT increased CD4^(+)Foxp3^(+)cells and Foxp3 expression ex vivo,and it enhanced the inhibitory function of inducible ***:HHT promotes Treg cell differentiation and enhances Treg suppressive function by attenuating the TCR signaling pathway and upregulating the expression of Treg signature genes and IL-10 levels,thereby promoting mouse heart allograft *** findings may have therapeutic implications for organ tr

关键词： Heart transplantation Homoharringtonine immunosuppressive agents T-lymphocytes,Regulatory Graft acceptance

Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2015年第4期14卷 374-379页

作者： Seong Hoon Kim Seung Duk Lee Young Kyu Kim Sang-Jae Park Center for Liver Cancer National Cancer Center 111 Jungbalsan-ro Ilsandong-gu Goyang-si Gyeonggi-do 410-769 Korea

Once-daily extended-release tacrolimus （Tac-OD） has been introduced as a useful therapeutic option to increase patient adherence to immunosuppressive therapy. This study aimed to evaluate the safety, efficacy and immunosuppressant adherence of conversion from twice-daily tacrolimus （Tac-BID） to Tac-OD in stable adult living donor liver transplant （LDLT） recipients in a single institution. METHODS： Between February and May 2013, Tac-BID was converted to Tac-OD in recipients followed up for at least 12 months after transplantation and without previous rejection episodes. The switching policy was based on a dose ratio of 1：1 with dose adjustment target trough levels at 3-5 ng/mL. Tacro- limus trough levels, laboratory parameters, metabolic disor- ders, and adverse events were assessed. RESULTS： A total of 229 patients were enrolled in the study. The median age at conversion was 53 years （range 31-73）. The median transplant duration was 35.3 months （range 12.0-95.4）. During a median follow-up of 13.5 months after conversion, 9 patients returned to Tac-BID because of adverse events. No acute rejection episodes were observed. Of 214 patients still on Tac-OD at 12 months, 12 （5.6%） received a reduced dose and 95 （44.4%） required an increased dose over baseline. Overall adherence was 82.2% at the end of follow-up. CONCLUSION： The conversion from Tac-BID to Tac-OD with similar target trough levels after conversion is safe and effec- tive for long-term stable LDLT patients.

关键词： liver transplantation living donor immunosuppressive agents tacrolimus

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan Xu Lai-Bang Luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi Guo Liu-Gen Lan Xu-Yong Sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-Qiang Li Mu-Jian Teng Jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-Hua Song Zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

Expert consensus on management of metabolic disease in Chinese liver transplant recipients

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第27期26卷 3851-3864页

作者： Tian Shen Li Zhuang Xiao-Dong Sun Xiao-Sheng Qi Zhi-Hui Wang Rui-Dong Li Wen-Xiu Chang Jia-Yin Yang Yang Yang Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003Zhejiang ProvinceChina Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalHangzhou 310003Zhejiang ProvinceChina Department of Hepatobiliary and Pancreas Surgery The First HospitalJilin UniversityChangchun 130021Jilin ProvinceChina Department of General Surgery Shanghai First People's HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200080China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052Henan ProvinceChina Department of General Surgery and Liver Transplant Center Huashan HospitalFudan UniversityShanghai 200040China Department of Nephrology Tianjin First Center HospitalTianjin 300384China Department of Liver Surgery and Liver Transplantation Center West China Hospital of Sichuan UniversityChengdu 610041Sichuan ProvinceChina Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630Guangdong ProvinceChina

Metabolic disease,including diabetes mellitus,hypertension,dyslipidemia,obesity,and hyperuricemia,is a common complication after liver transplantation and a risk factor for cardiovascular disease and *** development of metabolic disease is closely related to the side effects of ***,optimization of the immunosuppressive regimen is very important for the prevention and treatment of metabolic *** Chinese Society of Organ Transplantation has developed an expert consensus on the management of metabolic diseases in Chinese liver transplant recipients based on recent *** is placed on the risk factors of metabolic diseases,the effect of immunosuppressants on metabolic disease,and the prevention and treatment of metabolic diseases.

关键词： Liver transplantation Metabolic disease Diabetes mellitus Hypertension Dyslipidemia Hyperuricemia Obesity immunosuppressive agents Consensus

Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients’T cell ferroptosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2023年第20期29卷 3084-3102页

作者： Hao Wang Zheng-Lu Wang Sai Zhang De-Jun Kong Rui-Ning Yang Lei Cao Jian-Xi Wang Sei Yoshida Zhuo-Lun Song Tao Liu Shun-Li Fan Jia-Shu Ren Jiang-Hong Li Zhong-Yang Shen Hong Zheng The First Central Clinical School Tianjin Medical UniversityTianjin 300190China Department of Organ Transplant Tianjin First Central HospitalSchool of MedicineNankai UniversityTianjin 300190China Key Laboratory of Transplant Medicine Chinese Academy of Medical SciencesTianjin 300190China School of Medicine Nankai UniversityTianjin 300190China Research Institute of Transplant Medicine Nankai UniversityTianjin 300071China Tianjin Key Laboratory for Organ Transplantation Tianjin First Central HospitalSchool of MedicineNankai UniversityTianjin 300071China National Health Commission’s Key Laboratory for Critical Care Medicine Tianjin First Central HospitalTianjin 300071China

BACKGROUND Capecitabine(CAP)is a classic antimetabolic drug and has shown potential antirejection effects after liver transplantation(LT)in clinical *** previous study showed that metronomic CAP can cause the programmed death of T cells by inducing oxidative stress in healthy ***,a newly defined non-apoptotic cell death that occurs in response to iron overload and lethal levels of lipid peroxidation,is an important mechanism by which CAP induces cell ***,ferroptosis may also play an important role in CAP-induced T cell death and play an immunosuppressive role in acute rejection after *** To investigate the functions and underlying mechanisms of antirejection effects of metronomic *** A rat LT model of acute rejection was established,and the effect of metronomic CAP on splenic hematopoietic function and acute graft rejection was evaluated 7 d after *** vitro,primary CD3+T cells were sorted from rat spleens and human peripheral blood,and co-cultured with or without 5-fluorouracil(5-FU)(active agent of CAP).The levels of ferroptosis-related proteins,ferrous ion concentration,and oxidative stress-related indicators were *** changes in mitochondrial structure were observed using electron *** With no significant myelotoxicity,metronomic CAP alleviated graft injury(Banff score 9 vs 7.333,P<0.001),prolonged the survival time of the recipient rats(11.5 d vs 16 d,P<0.01),and reduced the infiltration rate of CD3+T cells in peripheral blood(6.859 vs 3.735,P<0.001),liver graft(7.459 vs 3.432,P<0.001),and spleen(26.92 vs 12.9,P<0.001),thereby inhibiting acute rejection after *** vitro,5-FU,an end product of CAP metabolism,induced the degradation of the ferritin heavy chain by upregulating nuclear receptor coactivator 4,which caused the accumulation of ferrous *** also inhibited nuclear erythroid 2 p45-related factor 2,heme oxygenase-1,and glutathione peroxidase 4,eventually leading to oxidati

关键词： Capecitabine Ferroptosis T Lymphocytes immunosuppressive agents Graft rejection Liver transplantation

Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots:A Review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2021年第4期9卷 568-575页

作者： Deepak Madhu Sanchit Sharma Ashish Agarwal Anoop Saraya Department of Gastroenterology Aster MIMS CalicutKeralaIndia Department of Gastroenterology Caritas HospitalKottayamKeralaIndia Department of Gastroenterology and Human Nutrition All India Institute of Medical SciencesNew DelhiIndia Department of Gastroenterology All India Institute of Medical SciencesJodhpurRajasthanIndia

The ongoing coronavirus disease-2019(COVID-19)pandemic has necessitated special considerations in the management of *** way presence of pre-existing diseases or treatment for it predisposes to,alters course of,and changes the management of COVID-19,is of relevance and is being extensively *** hepatitis(AIH)is unique in that it is an autoimmune disease mandating treatment with immunosuppressive drugs,as well as a liver disease with potential for varying degrees of underlying *** use of immunosuppressive drugs could alter the risk of acquiring COVID-19,the clinical course and severity of COVID-19 and the degree of underlying liver fibrosis could alter the clinical outcomes of patients with *** this review,we try to summarize key areas relevant in understanding and improving the clinical care of patients with AIH in the current *** considerations required in the management of patients with AIH in COVID-19 hotspots have been outlined based on the current evidence.

关键词： Hepatitis Autoimmune Liver cirrhosis COVID-19 SARS-CoV-2 infection immunosuppressive agents

Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第28期20卷 9253-9260页

作者： Marco Dall’Agata Annagiulia Gramenzi Maurizio Biselli Mauro Bernardi Semeiotica Medica - Policlinico S.Orsola-Malpighi Dipartimento di Scienze Mediche e ChirurgicheUniversity of Bologna

Recurrence of hepatitis C virus(HCV)infection following liver transplantation(LT)is almost universal and can accelerate graft cirrhosis in up to 30%of *** development of effective strategies to treat or prevent HCV recurrence after LT remains a major challenge,considering the shortage of donor organs and the accelerated progression of HCV in LT *** antiviral therapy with pegylated-interferon plus ribavirin is the current treatment of choice for HCV LT recipients,even though the combination is not as effective as it is in immunocompetent patients.A sustained virological response in the setting of LT improves patient and graft survival,but this is only achieved in 30%-45%of patients and the treatment is poorly *** improve the efficacy of pre-and post-transplant antiviral therapy,a new class of potent direct-acting antiviral agents (DAAs)has been *** aim of this review is to summarize the use of DAAs in LT HCV ***,Cochrane Library,MEDLINE,EMBASE,Web of Science and clinical trial databases were searched for this *** date,only three clinical studies on the topic have been published and most of the available data are in abstract *** a moderately successful early virological response has been reported,DAA treatment regimens were associated with severe toxicity mitigating their potential ***,the ongoing nature of data,the lack of randomized studies,the small number of enrolled patients and the heterogeneity of these studies make the results largely anecdotal and *** conclusion,large welldesigned clinical studies on DAAs in HCV LT patients are required before these drugs can be recommended after transplantation.

关键词： Hepatitis C virus Liver transplantation Direct antiviral agents Peginterferon/ribavirin immunosuppressive agents